Research Topics
Genomes and Genes | Ulrich DuhrsenSummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trialUlrich Duhrsen
Department of Hematology, University Hospital Essen, University of Duisburg Essen, Essen, Germany
Leuk Lymphoma 50:1757-60. 2009..So far, 175 patients have been enrolled of whom 128 have reached interim-PET scanning. In patients with a positive scan, relapses were six times more frequent than in patients with a negative scan. Recruitment into the trial continues...
Long-term outcome of hemizygous and heterozygous carriers of a germline GATA1 (G208R) mutationUlrich Duhrsen
Klinik für Hämatologie, Universitatsklinikum Essen, Hufelandstrasse 55, Essen, Germany
Ann Hematol 90:301-6. 2011....- FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, University of Duisburg Essen, Germany
Eur J Haematol 83:541-9. 2009..In multivariate analysis low FCRL2 expression was a significant independent prognostic factor (HR 2.4; P = 0.005). Here we demonstrate that the level of FCRL2 expression is correlated with prognosis in B-CLL... - Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft modelSemra Aydin
Department of Hematology, University of Duisburg Essen Medical School, Essen, Germany
Eur J Haematol 87:10-9. 2011..This model could be useful for evaluating the biological basis of CLL growth in the context of the hematopoietic microenvironment as well as preclinical testing of novel compounds... - Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemiaMaher Hanoun
Department of Hematology, University Hospital, Essen, Germany
PLoS ONE 7:e34347. 2012..We also compared the CRY1 expression in CLL with other lymphoid malignancies and observed epigenetic silencing of CRY1 in a patient with B cell acute lymphoblastic leukemia (B-ALL)... - Telomeres and prognosis in patients with chronic lymphocytic leukaemiaLudger Sellmann
Department of Haematology, University of Duisburg Essen, Essen, Germany
Int J Hematol 93:74-82. 2011..Short telomeres and high telomerase activity as occurs in some patients with CLL with a worse prognosis might be an ideal target for treatment with telomerase inhibitors... 
Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure--Feasibility, safety and effects on exercise tolerance and cardiac functionAndreas Hüttmann
Klinik für Hämatologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
Basic Res Cardiol 101:78-86. 2006..Sequential administration of G-CSF is feasible and possibly effective in improving physical performance in patients with chronic heart failure. Patients with ICM may be at risk of increased angina and arrhythmias...- p53 protein expression in chronic lymphocytic leukemiaLudger Sellmann
Department of Hematology, Medical Faculty, University of Duisburg Essen, Essen, Germany
Leuk Lymphoma 53:1282-8. 2012..Taken together, the differential expression of p53 isoforms could disrupt the p53 response and contribute to CLL pathogenesis... - Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patientsSemra Aydin
Department of Hematology, Medical Faculty, University of Duisburg Essen, Essen, Germany
Ann Hematol 86:271-6. 2007.... - Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemiaLothar Vassen
Institut für Zellbiologie Tumorforschung, IFZ, Universitatsklinikum Essen, Virchowstrasse 173, 45122 Essen, Germany
Int J Hematol 89:422-30. 2009.... - The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemiaUlrich H Frey
Institut für Pharmakogenetik, Universitatsklinikum Essen, Hufelandstrasse 55, D 45122 Essen, Germany
Clin Cancer Res 12:5686-92. 2006..The TT genotype of the GNAS1 T393C polymorphism is associated with increased Galphas transcript levels and a more favorable clinical course in different solid cancers... - The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levelsHagen S Bachmann
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg Essen, Duisburg, Germany
Eur J Haematol 85:108-13. 2010..Moreover, PSMA6 mRNA expression in human B-cell lines depended on genotypes. We investigated a potential role of this novel SNP in patients with MM... - Prevalence and incidence of anemia in the German Heinz Nixdorf Recall StudyLewin Eisele
Department of Hematology, University Hospital Essen, Essen, Germany
Ann Hematol 92:731-7. 2013..Participants with elevated FLC and high-sensitivity C-reactive protein (hsCRP) had an increased risk of anemia at 5-year FU. FLC-alone or in combination with hsCRP-may serve as biomarker indicating an increased risk of developing anemia... - Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in GermanyLewin Eisele
Department of Hematology, University Hospital Essen, Hufelandstr 55, 45122, Essen, Germany
Ann Hematol 91:243-8. 2012..7%, 95% CI 0.5-1.0). None of the LCMGUS cases progressed. We demonstrate a MGUS prevalence of 3.5% and a LCMGUS prevalence of 0.7% in the general population aged 45-75 years in Germany using a sensitive screening approach... - Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemiaLewin Eisele
Department of Hematology, University Hospital, Hufelandstrasse 55, Essen, Germany
Eur J Haematol 83:320-7. 2009..Because of their role in the expression of cell cycle-related and DNA-damage response genes, we suggest that the deregulated expression of circadian genes may be linked to the molecular pathogenesis of CLL... - Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costsLewin Eisele
Department of Hematology, University Hospital Essen, Germany
Onkologie 33:658-64. 2010..This study assessed the feasibility and safety of out of hospital management of acute myeloid leukemia (AML) patients during consolidation therapy... - Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemiaLewin Eisele
Department of Haematology, University Hospital, Essen, Germany
Leuk Res 33:775-8. 2009..By contrast, CD38 expression on T cells was not significantly associated with an adverse clinical outcome... - Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemiaAlexander Roth
Department of Haematology, University Hospital, Essen, Germany
Br J Haematol 143:383-6. 2008..This indicated an extensive expansion and a role for T-cells in ZAP-70(+)/CD38(+) CLL patients... - Prognostic significance of serum cystatin C in multiple myelomaHolger Nuckel
Department of Hematology, University Hospital Essen, Hufelandstr 55, 45122, Essen, Germany
Int J Hematol 95:545-50. 2012..The level of serum cystatin C is not only a sensitive marker of renal function, but also reflects tumor burden and delivers prognostic information in MM... - Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, Medical Faculty, University of Duisburg Essen, Germany
Blood 109:290-7. 2007..034) together with disease stage at diagnosis (HR 2.5; P = .004) and ZAP-70 status (HR 3.0; P = .001). The BCL2-938AA genotype is associated with increased Bcl-2 expression and a novel unfavorable genetic marker in patients with B-CLL... - Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)Oliver G Ottmann
Department of Hematology, University Hospital of Frankfurt, Germany
Cancer 109:2068-76. 2007..Imatinib in combination with intensive chemotherapy has yielded promising results as front-line therapy, but its value as monotherapy in newly diagnosed Ph+ALL is not known... - No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemiaKathrin Riemann
Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany
Pharmacogenet Genomics 16:783-8. 2006..The purpose of this study was, therefore, to investigate associations of the -94ins/delATTG polymorphism with susceptibility and survival of patients with different types of cancer... - Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemiaChristina A Ortmann
Klinik für Hämatologie, Zentrum für Konservative Onkologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Germany
Ann Hematol 87:809-18. 2008..Such a role is further supported by the observation that treatment of PRAME-negative cell lines U-937 and THP-1 with the demethylating agent 5'-Aza-2'dC resulted in a dose-related upregulation of PRAME expression... - High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemiaHolger Nuckel
Department of Haematology, University of Duisburg Essen, Germany
Clin Immunol 131:472-80. 2009..Collectively, our data confirm the prognostic significance supporting the idea to use CD49d as target molecules for therapeutic approaches in B-CLL... - Rapid succession of peripheral blood progenitor cell mobilization cycles in patients with chronic heart failure: effects on the hematopoietic systemAndreas Hüttmann
Hematology Clinic and the Cardiology Clinic, Center for Internal Medicine, University Hospital, Essen, Germany
Transfusion 46:1424-31. 2006..The safety and cardiovascular efficacy data have been described elsewhere. In the hematopoietic system, the trial offered an opportunity to study several new aspects of granulocyte-colony-stimulating factor (G-CSF) action... - Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemiaLudger Sellmann
Department of Haematology, Medical Faculty, University of Duisburg Essen, Essen, Germany
Br J Haematol 138:217-20. 2007..Karyotypes of the present study and the literature identified a strong correlation to trisomy 18 in addition to trisomy 12. Trisomy 19 seems to be a secondary event in B-CLL with trisomy 12, mostly originating from mutated B cells... - Gene dosage effects in chronic lymphocytic leukemiaLudger Sellmann
Department of Hematology, Medical Faculty, University of Duisburg Essen, Hufelandstrase 55, 45122 Essen, Germany
Cancer Genet Cytogenet 203:149-60. 2010..We did not confirm a consistent correlation between MIRN15A and MIRN16-1 expression levels and BCL2 protein levels, indicating a complex regulation of BCL2 expression... - Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, University Hospital Essen, Essen, Germany
Leuk Lymphoma 47:1053-61. 2006..The LPL/ADAM29 expression ratio was not found to be an independent prognostic factor and did not offer any advantages over the use of LPL alone. Collectively, our data confirm a role for LPL as a novel prognostic indicator in B-CLL... - Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center studyHannes Müller-Beissenhirtz
Klinik für Hämatologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Germany
Ann Hematol 84:796-801. 2005..There was no treatment-related mortality. GVP shows substantial activity in poor prognosis relapsed or refractory aggressive lymphomas and is generally well tolerated, but haematological toxicity is dose limiting... - Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumabAlexander Roth
Department of Hematology, West German Cancer Center, University Hospital Essen, Germany
Eur J Haematol 87:473-9. 2011.... - Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomenaAlexander Roth
Department of Hematology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany
Int J Hematol 93:704-14. 2011..Iron should not be routinely supplemented in PNH patients treated with eculizumab without close monitoring of iron parameters, and iron depletion therapy should be considered in the case of overload... - A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the diseaseJan Dürig
Department of Hematology, University of Duisburg Essen Medical School, Essen, Germany
Cancer Res 67:8653-61. 2007..These results suggest that this model reflects the heterogeneity and important clinical characteristics of the disease, and thus may serve as a tool for preclinical drug testing and investigation of the pathophysiology of CLL... - Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometryHolger Nuckel
Department of Haematology, University of Duisburg Essen Medical Centre, Essen, Germany
Clin Lab Haematol 28:22-9. 2006..When combined with conventional cytology, flow cytometric analysis improves the detection rate of CSF involvement in patients with haematological malignancies. It is particularly useful in B cell neoplasms with low CSF cell numbers... - HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implicationsVera Rebmann
Institut fur Immunologie, Universitatsklinikum Essen, Virchowstr 171, D 45122 Essen, Germany
Semin Cancer Biol 17:430-5. 2007..The corresponding immunological parameters point to a broad immunosuppression in these patients. Thus, HLA-G seems to contribute to the impaired immune response in B-CLL supporting disease progression... - 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcomeHolger Nuckel
Department of Hematology, Medical Faculty, University of Essen, Essen, Germany
Eur J Haematol 72:259-63. 2004..In conclusion, our data do not support a role of the P2X7 genotype as a prognostic marker in B-cell CLL... - Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemiaJan Dürig
Department of Hematology, Medical Faculty, University of Essen, Germany
Blood 101:2748-55. 2003..05). Our data show that gene expression profiling can help identify B-CLL subtypes with different clinical characteristics. Furthermore, our results suggest a role of translation-associated genes in the pathogenesis of B-CLL... - Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicityHolger Nuckel
Department of Hematology, Medical School, University of Duisburg Essen, Germany
Eur J Pharmacol 514:217-24. 2005..Alemtuzumab significantly enhances apoptosis in chronic lymphocytic leukemia cells in vitro, especially in combination with a cross-linking anti-Fc-antibody, this effect being mediated by a caspase-dependent pathway... - Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctivaHolger Nuckel
Department of Hematology, Medical Faculty, University of Essen, Germany
Eur J Haematol 73:258-62. 2004..Rituximab is a highly effective and well-tolerated treatment of conjunctival MALT lymphoma, which may not only be of value in relapse, but also in cases of contraindication to radiotherapy... - The CC genotype of the C825T polymorphism of the G protein beta3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemiaHolger Nuckel
Department of Haematology, University of Essen Medical School, Hufelandstrasse 55, 45122 Essen, Germany
Leuk Lymphoma 44:1739-43. 2003..0043). The GNB3 genotype (p = 0.024) and age (p = 0.042) were identified as independent prognostic factors for a second therapy. Thus, the long-term success of the treatment appears to be correlated with the GNB3 genotype... - Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcomeDaniel Patschan
Department of Nephrology, University Hospital, Essen, University of Duisburg-Essen, Germany
Nephrol Dial Transplant 21:1549-54. 2006..AMI occurs especially in TTP, and serum LDH above 1,000 U/l in combination with serum troponin I above 0.20 ng/ml at TMA presentation are excellent predictors of subsequent AMI...